NCT00770848 2014-03-10
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Amgen
Phase 1/2 Completed
Amgen
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
National Cancer Institute (NCI)
Sanofi